Showing 2221-2230 of 9226 results for "".
- Swiftscope App Integrates Dermatoscopy With SwiftPro Wart Treatmentshttps://practicaldermatology.com/news/swiftscope-app-integrates-dermatoscopy-with-swiftpro-wart-treatments/2487231/Emblation has launched the Swiftscope app, a new digital imaging platform designed to help clinicians visually monitor treatment progress in patients undergoing SwiftPro microwave therapy for common and plantar warts, according to a news release. The announcement f
- Ultrasound Detects Subclinical Joint and Nail Changes in Pediatric Psoriasishttps://practicaldermatology.com/news/ultrasound-detects-subclinical-joint-and-nail-changes-in-pediatric-psoriasis/2487206/Musculoskeletal ultrasound may help identify early inflammatory changes in children with psoriasis before the onset of clinically apparent arthritis, according to findings from a pilot study evaluating joint, entheseal, and nail abnormalities in pediatric patients.
- Review: Botulinum Toxin Shows Potential in Acne Treatmenthttps://practicaldermatology.com/news/systematic-review-highlights-botulinum-toxins-potential-in-acne-treatment/2487204/Botulinum toxin A may offer a potential adjunctive treatment option for both acne vulgaris and acne scarring, according to a recent systematic review published in the Journal of Drugs in Dermatology. Botulinum Toxin S
- FDA Approves OTC Switch for Galderma’s Differin Epiduo Acne Gelhttps://practicaldermatology.com/news/fda-approves-otc-switch-for-galdermas-differin-epiduo-acne-gel/2487203/The US Food and Drug Administration (FDA) has approved Galderma’s Differin Epiduo Acne Gel (adapalene 0.1% and benzoyl peroxide 2.5%) for over-the-counter (OTC) use in patients aged 12 years and older, marking a notable prescription-to-OTC transition in acne therap
- BE BOLD: Bimekizumab Tops Risankizumab for ACR50 Outcomeshttps://practicaldermatology.com/news/be-bold-bimekizumab-tops-risankizumab-for-acr50-outcomes/2487139/New phase 3 data from the BE BOLD trial indicated that bimekizumab (BIMZELX) achieved superior joint efficacy compared with risankizumab (SKYRIZI) in adults with active psoriatic arthritis (PsA), according to a press release from the manufacturer.
- From SCALE 2026: Practical Strategies for Treating GLP-1–Related Aesthetic Changeshttps://practicaldermatology.com/news/from-scale-2026-practical-strategies-for-treating-glp-1related-aesthetic-changes/2487118/At the 2026 Music City SCALE meeting, Terrence Keaney, MD, discussed how dermatologists can proactively address facial aging, skin laxity, hair loss, and muscle loss associated with GLP-1–mediated weight reduction, outlining a practical framework for managing some of the aesthetic issues related
- From SCALE 2026: Dermatologists Navigate the Expanding Role of GLP-1s in Skin Health and Aesthetic Carehttps://practicaldermatology.com/news/dermatologists-navigate-the-expanding-role-of-glp-1s-in-skin-health-and-aesthetic-care/2487095/As use of GLP-1 receptor agonists continues to surge, dermatologists are increasingly encountering the downstream effects of these medications in both medical and cosmetic practice. During a session at the 2026 Music City SCALE meeting in Nashville, dermatologist and researcher Glynis Ablon, MD,
- Combination Ixekizumab and Tirzepatide Therapy Outperforms Ixekizumab Alone in Psoriasishttps://practicaldermatology.com/news/combination-ixekizumab-and-tirzepatide-therapy-outperforms-ixekizumab-alone-in-psoriasis/2487115/Concomitant treatment with ixekizumab (Taltz, Eli Lilly and Company) and tirzepatide (Zepbound, Eli Lilly and Company) led to superior skin clearance and quality-of-life outcomes compared with ixekizumab alone in adults with moderate-to-severe plaque psoriasis and
- Global Skin Cancer Burden Projected to Rise Through 2050: Studyhttps://practicaldermatology.com/news/global-skin-cancer-burden-projected-to-rise-through-2050/2487086/A new research letter published online in JAMA Dermatology highlights widening global disparities in skin cancer burden and projects continued increases in melanoma, cutaneous squamous cell carcinoma (cSCC), and basal cell c
- Long-Term Dupilumab Use Linked to Delayed Relapse in AD: Studyhttps://practicaldermatology.com/news/long-term-dupilumab-use-linked-to-delayed-relapse-in-ad-study/2487027/Patients with moderate-to-severe atopic dermatitis (AD) treated with dupilumab experienced durable symptom control and delayed relapse with long-term therapy, according to a real-world retrospective study published in the Journal